CA2588767A1 - Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues - Google Patents

Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues Download PDF

Info

Publication number: CA2588767A1
Authority: CA; Canada
Prior art keywords: cocaine; carrier; hapten; antibody; drug
Prior art date: 1995-03-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002588767A

Other languages

English (en)

Inventor

Philip A. Swain

Victoria C. Schad

Julia L. Greenstein

Mark A. Exley

Barbara S. Fox

Stephen P. Powers

Malcolm L. Gefter

Thomas J. Briner

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Xenova Research Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-31

Filing date

1996-03-27

Publication date

1996-10-03

1995-11-28 Priority claimed from US08/563,673 external-priority patent/US5760184A/en

1996-03-27 Application filed by Individual filed Critical Individual

1996-03-27 Priority to CA2770491A priority Critical patent/CA2770491A1/fr

1996-03-27 Priority claimed from CA002216658A external-priority patent/CA2216658C/fr

1996-10-03 Publication of CA2588767A1 publication Critical patent/CA2588767A1/fr

Status Abandoned legal-status Critical Current

Links

208000011117 substance-related disease Diseases 0.000 title claims abstract description 23
238000002560 therapeutic procedure Methods 0.000 title description 22
206010013654 Drug abuse Diseases 0.000 title description 14
230000001225 therapeutic effect Effects 0.000 claims abstract description 60
238000011282 treatment Methods 0.000 claims abstract description 31
206010013663 drug dependence Diseases 0.000 claims abstract description 29
108090000623 proteins and genes Proteins 0.000 claims description 39
102000004169 proteins and genes Human genes 0.000 claims description 37
-1 viral subunits Substances 0.000 claims description 23
108091007433 antigens Proteins 0.000 claims description 22
102000036639 antigens Human genes 0.000 claims description 22
238000002255 vaccination Methods 0.000 claims description 22
239000002671 adjuvant Substances 0.000 claims description 21
239000000427 antigen Substances 0.000 claims description 21
210000001744 T-lymphocyte Anatomy 0.000 claims description 19
108090000765 processed proteins & peptides Proteins 0.000 claims description 19
229940037003 alum Drugs 0.000 claims description 17
238000002360 preparation method Methods 0.000 claims description 17
239000000047 product Substances 0.000 claims description 17
102000004196 processed proteins & peptides Human genes 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
206010012335 Dependence Diseases 0.000 claims description 9
229960002715 nicotine Drugs 0.000 claims description 6
230000002459 sustained effect Effects 0.000 claims description 5
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
239000004005 microsphere Substances 0.000 claims description 4
238000012986 modification Methods 0.000 claims description 4
230000004048 modification Effects 0.000 claims description 4
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 4
230000000699 topical effect Effects 0.000 claims description 4
108090001090 Lectins Proteins 0.000 claims description 3
102000004856 Lectins Human genes 0.000 claims description 3
239000000443 aerosol Substances 0.000 claims description 3
229920001577 copolymer Polymers 0.000 claims description 3
239000002523 lectin Substances 0.000 claims description 3
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
102000002067 Protein Subunits Human genes 0.000 claims description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
230000002500 effect on skin Effects 0.000 claims description 2
239000003380 propellant Substances 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims 10
230000001580 bacterial effect Effects 0.000 claims 2
108010077805 Bacterial Proteins Proteins 0.000 claims 1
239000013065 commercial product Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 123
229940079593 drug Drugs 0.000 abstract description 122
238000000034 method Methods 0.000 abstract description 81
238000002649 immunization Methods 0.000 abstract description 63
230000003053 immunization Effects 0.000 abstract description 60
239000000203 mixture Substances 0.000 abstract description 58
201000009032 substance abuse Diseases 0.000 abstract description 19
238000001727 in vivo Methods 0.000 abstract description 18
208000022497 Cocaine-Related disease Diseases 0.000 abstract description 16
201000006145 cocaine dependence Diseases 0.000 abstract description 11
238000011262 co‐therapy Methods 0.000 abstract description 3
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 620
229960003920 cocaine Drugs 0.000 description 362
108010049048 Cholera Toxin Proteins 0.000 description 107
102000009016 Cholera Toxin Human genes 0.000 description 107
241000699670 Mus sp. Species 0.000 description 103
239000000243 solution Substances 0.000 description 72
230000005875 antibody response Effects 0.000 description 46
230000004044 response Effects 0.000 description 44
AYDBLCSLKNTEJL-RFQIPJPRSA-N Norcocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 AYDBLCSLKNTEJL-RFQIPJPRSA-N 0.000 description 43
235000018102 proteins Nutrition 0.000 description 36
230000000694 effects Effects 0.000 description 32
238000002965 ELISA Methods 0.000 description 31
150000001875 compounds Chemical class 0.000 description 30
108010078791 Carrier Proteins Proteins 0.000 description 28
102000014914 Carrier Proteins Human genes 0.000 description 28
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
241001465754 Metazoa Species 0.000 description 26
238000009826 distribution Methods 0.000 description 26
241000700159 Rattus Species 0.000 description 25
238000002347 injection Methods 0.000 description 25
239000007924 injection Substances 0.000 description 25
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
229960005486 vaccine Drugs 0.000 description 23
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 22
238000013459 approach Methods 0.000 description 21
210000002966 serum Anatomy 0.000 description 21
230000021615 conjugation Effects 0.000 description 20
210000004556 brain Anatomy 0.000 description 19
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
238000000502 dialysis Methods 0.000 description 17
238000012360 testing method Methods 0.000 description 17
238000010183 spectrum analysis Methods 0.000 description 16
238000002474 experimental method Methods 0.000 description 15
239000002207 metabolite Substances 0.000 description 15
239000000872 buffer Substances 0.000 description 14
238000004519 manufacturing process Methods 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
238000003556 assay Methods 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
239000002904 solvent Substances 0.000 description 13
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
239000000969 carrier Substances 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
230000028993 immune response Effects 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 12
235000002639 sodium chloride Nutrition 0.000 description 12
241000282412 Homo Species 0.000 description 11
150000002148 esters Chemical class 0.000 description 11
238000004458 analytical method Methods 0.000 description 10
QIQNNBXHAYSQRY-UHFFFAOYSA-N ecgonine methyl ester Natural products C1C(O)C(C(=O)OC)C2CCC1N2C QIQNNBXHAYSQRY-UHFFFAOYSA-N 0.000 description 10
QIQNNBXHAYSQRY-UYXSQOIJSA-N ecgonine methyl ester Chemical compound C1[C@H](O)[C@H](C(=O)OC)[C@H]2CC[C@@H]1N2C QIQNNBXHAYSQRY-UYXSQOIJSA-N 0.000 description 10
230000006698 induction Effects 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
238000007912 intraperitoneal administration Methods 0.000 description 10
238000000746 purification Methods 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
229960003914 desipramine Drugs 0.000 description 9
125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 9
KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
108060003951 Immunoglobulin Proteins 0.000 description 8
125000003277 amino group Chemical group 0.000 description 8
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
229960001736 buprenorphine Drugs 0.000 description 8
GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 8
102000018358 immunoglobulin Human genes 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
150000004702 methyl esters Chemical class 0.000 description 8
230000003472 neutralizing effect Effects 0.000 description 8
239000000843 powder Substances 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
238000002835 absorbance Methods 0.000 description 7
238000001990 intravenous administration Methods 0.000 description 7
229940074404 sodium succinate Drugs 0.000 description 7
ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
230000009885 systemic effect Effects 0.000 description 7
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
230000006399 behavior Effects 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
230000003197 catalytic effect Effects 0.000 description 6
PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 description 6
PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 description 6
239000012530 fluid Substances 0.000 description 6
230000002163 immunogen Effects 0.000 description 6
238000001802 infusion Methods 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
239000011347 resin Substances 0.000 description 6
229920005989 resin Polymers 0.000 description 6
239000000523 sample Substances 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
229940014800 succinic anhydride Drugs 0.000 description 6
229940021747 therapeutic vaccine Drugs 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
238000012549 training Methods 0.000 description 6
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
230000003213 activating effect Effects 0.000 description 5
239000012752 auxiliary agent Substances 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
239000011324 bead Substances 0.000 description 5
210000005013 brain tissue Anatomy 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
201000001272 cocaine abuse Diseases 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
239000003480 eluent Substances 0.000 description 5
238000003818 flash chromatography Methods 0.000 description 5
150000002270 gangliosides Chemical group 0.000 description 5
230000001939 inductive effect Effects 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
239000000178 monomer Substances 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
125000003396 thiol group Chemical group [H]S* 0.000 description 5
XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical group C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 5
238000011725 BALB/c mouse Methods 0.000 description 4
239000005711 Benzoic acid Substances 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
238000012286 ELISA Assay Methods 0.000 description 4
206010015535 Euphoric mood Diseases 0.000 description 4
229910004373 HOAc Inorganic materials 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
206010037742 Rabies Diseases 0.000 description 4
241000906446 Theraps Species 0.000 description 4
239000013566 allergen Substances 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
235000010233 benzoic acid Nutrition 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
238000011278 co-treatment Methods 0.000 description 4
230000008034 disappearance Effects 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
230000016784 immunoglobulin production Effects 0.000 description 4
238000013383 initial experiment Methods 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
239000008188 pellet Substances 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
239000013598 vector Substances 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
241001539473 Euphoria Species 0.000 description 3
239000007821 HATU Substances 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
101710120037 Toxin CcdB Proteins 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 3
229960002802 bromocriptine Drugs 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000003118 drug derivative Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
235000013305 food Nutrition 0.000 description 3
238000009472 formulation Methods 0.000 description 3
QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 3
239000000499 gel Substances 0.000 description 3
244000144993 groups of animals Species 0.000 description 3
210000005003 heart tissue Anatomy 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
230000000521 hyperimmunizing effect Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000005923 long-lasting effect Effects 0.000 description 3
235000018977 lysine Nutrition 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
210000003097 mucus Anatomy 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000006461 physiological response Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000037452 priming Effects 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
238000003345 scintillation counting Methods 0.000 description 3
230000000391 smoking effect Effects 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
230000001629 suppression Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
210000003437 trachea Anatomy 0.000 description 3
230000007704 transition Effects 0.000 description 3
WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical class [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 2
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 2
PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 2
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 2
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 2
240000006890 Erythroxylum coca Species 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
102000011931 Nucleoproteins Human genes 0.000 description 2
108010061100 Nucleoproteins Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102000004389 Ribonucleoproteins Human genes 0.000 description 2
108010081734 Ribonucleoproteins Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001266 acyl halides Chemical class 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
229930013930 alkaloid Natural products 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
230000004075 alteration Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229940125644 antibody drug Drugs 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000000546 chi-square test Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
238000009223 counseling Methods 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
238000011461 current therapy Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001784 detoxification Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
229960002069 diamorphine Drugs 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
229960002464 fluoxetine Drugs 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
125000001841 imino group Chemical group [H]N=* 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
150000002540 isothiocyanates Chemical class 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
229960004194 lidocaine Drugs 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
229960001797 methadone Drugs 0.000 description 2
244000005700 microbiome Species 0.000 description 2
108091005573 modified proteins Proteins 0.000 description 2
102000035118 modified proteins Human genes 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
229960004127 naloxone Drugs 0.000 description 2
239000013642 negative control Substances 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
238000011422 pharmacological therapy Methods 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000003014 reinforcing effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
235000013024 sodium fluoride Nutrition 0.000 description 2
239000011775 sodium fluoride Substances 0.000 description 2
CKYLHMGDNIAAPE-UHFFFAOYSA-M sodium;4-hydroxy-3-nitrobenzenesulfonate Chemical compound [Na+].OC1=CC=C(S([O-])(=O)=O)C=C1[N+]([O-])=O CKYLHMGDNIAAPE-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
208000003265 stomatitis Diseases 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
238000011285 therapeutic regimen Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
150000003813 tropane derivatives Chemical class 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
208000005925 vesicular stomatitis Diseases 0.000 description 2
238000001262 western blot Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
IPVYMXZYXFFDGW-UHFFFAOYSA-N 1-methylpiperidin-4-ol;hydrochloride Chemical compound Cl.CN1CCC(O)CC1 IPVYMXZYXFFDGW-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
GVGYEFKIHJTNQZ-UHFFFAOYSA-N 3-benzoyloxy-8-methyl-8-azoniabicyclo[3.2.1]octane-4-carboxylate Chemical compound CN1C(C2)CCC1C(C(O)=O)C2OC(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
230000005730 ADP ribosylation Effects 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
206010048610 Cardiotoxicity Diseases 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108010060123 Conjugate Vaccines Proteins 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
208000003870 Drug Overdose Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
102000047352 Esterase-like Human genes 0.000 description 1
108700037229 Esterase-like Proteins 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
101710154643 Filamentous hemagglutinin Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108091006054 His-tagged proteins Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
240000006568 Lathyrus odoratus Species 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
208000026251 Opioid-Related disease Diseases 0.000 description 1
239000008896 Opium Substances 0.000 description 1
206010033296 Overdoses Diseases 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
244000184734 Pyrus japonica Species 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010073443 Ribi adjuvant Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
108010079723 Shiga Toxin Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
241000723873 Tobacco mosaic virus Species 0.000 description 1
208000006633 Tonic-Clonic Epilepsy Diseases 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
235000010726 Vigna sinensis Nutrition 0.000 description 1
244000042314 Vigna unguiculata Species 0.000 description 1
VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 1
WOMVCHDWNFNAGP-UHFFFAOYSA-N [4-(hydroxymethyl)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] benzoate Chemical compound CN1C(C2)CCC1C(CO)C2OC(=O)C1=CC=CC=C1 WOMVCHDWNFNAGP-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
PWAXUOGZOSVGBO-UHFFFAOYSA-N adipoyl chloride Chemical compound ClC(=O)CCCCC(Cl)=O PWAXUOGZOSVGBO-UHFFFAOYSA-N 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
150000001649 bromium compounds Chemical class 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229930003827 cannabinoid Natural products 0.000 description 1
239000003557 cannabinoid Substances 0.000 description 1
229940065144 cannabinoids Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
231100000259 cardiotoxicity Toxicity 0.000 description 1
230000007681 cardiovascular toxicity Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
229960005004 cholera vaccine Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000035602 clotting Effects 0.000 description 1
235000008957 cocaer Nutrition 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
239000000571 coke Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
229940031670 conjugate vaccine Drugs 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940028617 conventional vaccine Drugs 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000000747 designer drug Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
239000012954 diazonium Substances 0.000 description 1
150000001989 diazonium salts Chemical class 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000021245 dietary protein Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
229960003983 diphtheria toxoid Drugs 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
230000002825 dopamine reuptake Effects 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
231100000725 drug overdose Toxicity 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000706 effect on dopamine Effects 0.000 description 1
230000009982 effect on human Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000002743 euphoric effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
229960003528 flurazepam Drugs 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
239000000380 hallucinogen Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
RIPPXFWUYXTRNJ-BHARVXRSSA-N hydron;methyl (1s,3s,4r,5r)-3-benzoyloxy-8-azabicyclo[3.2.1]octane-4-carboxylate;chloride Chemical compound Cl.O([C@H]1C[C@@H]2CC[C@@H](N2)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 RIPPXFWUYXTRNJ-BHARVXRSSA-N 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 1
OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 1
AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 1
210000004201 immune sera Anatomy 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
230000028270 inhibition of dopamine uptake Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229960002803 methaqualone Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
OJFHSUCSTHZNRW-UHFFFAOYSA-N methyl 3-(2-bromoacetyl)oxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1C(OC(=O)CBr)C(C(=O)OC)C2CCC1N2C OJFHSUCSTHZNRW-UHFFFAOYSA-N 0.000 description 1
AYDBLCSLKNTEJL-UHFFFAOYSA-N methyl 3-benzoyloxy-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound COC(=O)C1C(N2)CCC2CC1OC(=O)C1=CC=CC=C1 AYDBLCSLKNTEJL-UHFFFAOYSA-N 0.000 description 1
ZPUCINDJVBIVPJ-UHFFFAOYSA-N methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound COC(=O)C1C(N2C)CCC2CC1OC(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-UHFFFAOYSA-N 0.000 description 1
229960001344 methylphenidate Drugs 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000016379 mucosal immune response Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003982 neuronal uptake Effects 0.000 description 1
230000001962 neuropharmacologic effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960001027 opium Drugs 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
108091000699 pea lectin Proteins 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
229960003209 phenmetrazine Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
210000005215 presynaptic neuron Anatomy 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000011809 primate model Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
150000003233 pyrroles Chemical class 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012508 resin bead Substances 0.000 description 1
230000036387 respiratory rate Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003333 secondary alcohols Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000008362 succinate buffer Substances 0.000 description 1
230000035322 succinylation Effects 0.000 description 1
238000010613 succinylation reaction Methods 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
238000006177 thiolation reaction Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000008791 toxic response Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
229930004668 tropane alkaloid Natural products 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA002588767A 1995-03-31 1996-03-27 Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues Abandoned CA2588767A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2770491A CA2770491A1 (fr)	1995-03-31	1996-03-27	Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US41497195A	1995-03-31	1995-03-31
US08/414,971		1995-03-31
US08/563,673		1995-11-28
US08/563,673 US5760184A (en)	1995-03-31	1995-11-28	Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CA002216658A CA2216658C (fr)	1995-03-31	1996-03-27	Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002216658A Division CA2216658C (fr)	1995-03-31	1996-03-27	Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2770491A Division CA2770491A1 (fr)	1995-03-31	1996-03-27	Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues

Publications (1)

Publication Number	Publication Date
CA2588767A1 true CA2588767A1 (fr)	1996-10-03

Family

ID=38337974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002588767A Abandoned CA2588767A1 (fr)	1995-03-31	1996-03-27	Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues

Country Status (1)

Country	Link
CA (1)	CA2588767A1 (fr)

1996
- 1996-03-27 CA CA002588767A patent/CA2588767A1/fr not_active Abandoned

Publication	Publication Date	Title
US5876727A (en)	1999-03-02	Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5760184A (en)	1998-06-02	Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CA2216658C (fr)	2008-05-13	Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues
US20100209449A1 (en)	2010-08-19	Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO1998014216A9 (fr)	1998-08-13	Conjugues haptene-porteur destines a etre utilises dans une therapie pour toxicomanes et procedes de preparation de ceux-ci
AU776410B2 (en)	2004-09-09	Hapten-carrier conjugates for use in drug-abuse therapy
CA2588767A1 (fr)	1996-10-03	Conjugues vecteurs de haptene utilises dans une therapie contre l'usage de drogues
HK1103034A (en)	2007-12-14	Hapten-carrier conjugates for use in drug-abuse therapy (nicotine)
HK1103035A (en)	2007-12-14	Hapten-carrier conjugates for use in drug-abuse therapy (cocaine)
HK1103036A (en)	2007-12-14	Hapten-carrier conjugates for use in drug-abuse therapy
HK1027293B (en)	2008-05-09	Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
HK1110794A (en)	2008-07-25	Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same

Legal Events

Date	Code	Title	Description
2007-05-22	EEER	Examination request
2012-05-22	EEER	Examination request	Effective date: 20070522
2013-04-29	FZDE	Dead	Effective date: 20130304